Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.

Abstract

We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days.

• Authors: W Nagi, Z Y Lim, P Krishnamurthy, V Potter, V Tindell, L Reiff-Zall, A Abdullah, N Lea, M Kenyon, J Marsh, A Y L Ho, G J Mufti, A Pagliuca
• Journal: Leukemia research (Leuk Res) Vol. 35 Issue 8 Pg. 998-1000 (Aug 2011) ISSN: 1873-5835 [Electronic] England
• PMID: 21704371 (Publication Type: Journal Article)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm
• Alemtuzumab
• Vidarabine
• Busulfan
• fludarabine

Topics

• Alemtuzumab
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Busulfan (administration & dosage)
• Combined Modality Therapy
• Female
• Follow-Up Studies
• Graft vs Host Disease (prevention & control)
• Hematopoietic Stem Cell Transplantation
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local (pathology, therapy)
• Primary Myelofibrosis (pathology, therapy)
• Remission Induction
• Survival Rate
• Transplantation Conditioning
• Transplantation, Homologous
• Treatment Outcome
• Vidarabine (administration & dosage, analogs & derivatives)